THERADIAG Announces CE Marking Approval For Its New I-Track10 Automated Analyzer For Biotherapy Monitoring

THERADIAG, a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained the CE marking for its i-Track10 automated analyzer for biotherapy monitoring.

One of the key points of the agreement signed last April with IDS, which manufactures diagnostic test kits and instruments for the clinical market, was the access to their cutting-edge analyzer named
i-Track10.

Manufactured by IDS for Theradiag, this latest generation analyser is the first to be fully compatible with the full range of biotherapy monitoring products. It allows continuous loading, random access analysis and integration into laboratory automation systems.

The CE marking application for i-Track10 is now complete and its market launch has been registered with the French National Drug and Health Product Safety Agency (ANSM).

Internal assessments have confirmed the reliability, flexibility and analyzing speed of the device and independent evaluations have been scheduled to start over the coming weeks.

Feedback from initial presentations to customers and distributors have confirmed the interest and relevance of this unique innovative automated solution.